Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
69 hedge funds and large institutions have $62.4M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 12 closing their positions.
225% more call options, than puts
Call options by funds: $934K | Put options by funds: $287K
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding
Funds holding: 69 → 69 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $65.2M → $62.4M (-$2.79M)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$1.15M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$764K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$529K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$105K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$87.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.88M |
| 2 |
Morgan Stanley
New York
|
-$1.53M |
| 3 |
Two Sigma Investments
New York
|
-$582K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$408K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$296K |
VIRX Hedge Fund Activity: Q1 2022 in Review
69 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2022, worth a combined $62.4M — down 4.3% from $65.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VIRX positions and 12 closed out — a net gain of 1 holder — while 13 added to existing stakes and 23 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $1.15M. The largest seller was Vanguard Group, cutting an estimated $1.88M.
- 69 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $62.4M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2022, down 4.3% quarter-over-quarter.
- 13 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2022 and 12 closed out, a net change of +1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2022 was MAI Capital Management, an estimated $1.15M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2022 was Vanguard Group, an estimated $1.88M sold.
Based on aggregated 13F filings for Q1 2022.